By Scott Hewitt CEO and Vincent R. James Ph.D. CTO
Community BioRefineries,

Plant-Based Protein Isolates as a Foundation for Cachexia Management:
The Community BioRefinery's Nutritional Trilogy and Its Role in Supporting Cancer Recovery

Abstract
The loss of a loved one to cancer-associated cachexia (CAC) in the 1980s inspired a decades-long pursuit of solutions for this devastating syndrome, characterized by skeletal muscle wasting, systemic inflammation, and metabolic dysregulation. Affecting 50–80% of advanced cancer patients and up to 60% of those with HIV/AIDS, CAC contributes to ~20% of cancer-related mortality, impairing physical function and quality of life (QOL). Simple caloric intake, such as eating a hamburger, fails to reverse CAC due to its complex pathophysiology. Recent research highlights plant-based protein isolates as a tool to support weight maintenance and provide a physical foundation for cancer therapies, though not a cure. The Community BioRefinery (CBR) leverages sustainable, solvent-free technology to produce a nutritional trilogy—true 90%+ pure plant protein isolates, resistant starch, and high oleic acid (HOA) oil - designed to address muscle loss, inflammation, malabsorption, and anorexia. This paper explores CAC's mechanisms, patient experiences, the Texas A&M clinical trial on plant-based diets, and new evidence on plant-based protein isolates, proposing a CBR-derived "magic bullet" formulation that aligns with Orgain's mission for clean, recovery-focused nutrition.

A Personal Quest Born from Loss
In the 1980s, my wife was diagnosed with advanced cancer, a battle that introduced us to the cruel reality of cancer-associated cachexia (CAC). As her cancer progressed, cachexia stripped away her muscle and strength, leaving her frail and fatigued. We tried everything—soups, shakes, her favorite meals—but no amount of food, not even a hearty hamburger, could halt her decline. The doctors explained that cachexia wasn't just about eating more; it was a metabolic storm fueled by her cancer, rendering calories and nutrients ineffective. Her struggle, and her eventual passing, ignited a lifelong mission to find solutions for others facing this devastating condition. At the Community BioRefinery, we're channeling that mission into a plant-based nutritional trilogy, rooted in science and sustainability, to give cancer patients a physical foundation to support their therapies and recovery.

Cachexia: The Cancer Patient's Struggle
Cancer-associated cachexia (CAC) is a multifactorial syndrome defined by involuntary weight loss (>5% in 6 months or >2% with BMI <20 kg/m²), skeletal muscle depletion (sarcopenia**), and systemic inflammation, affecting 50–80% of advanced cancer patients (e.g., pancreatic, lung, colorectal) and 20–60% of those with HIV/AIDS (Fearon et al., 2011; Web:1, Web:2). For a cancer patient, a cachexia diagnosis compounds the physical and emotional burden of their disease, manifesting as:

- **Physical Decline**: Muscle wasting causes profound weakness, making tasks like walking, climbing stairs, or lifting objects difficult. Fatigue is relentless, increasing fall risk and dependency (Web:4).
- **Anorexia and Sensory Changes**: Tumor-derived factors (e.g., GDF-15), cytokines (TNF-α, IL-6), and chemotherapy-induced nausea or taste alterations suppress appetite, making eating unappealing (Web:5).
- **Systemic Effects**: Protein depletion impairs immune function, increasing infection risk, while inflammation elevates cardiovascular strain, potentially reducing cardiac muscle mass (Web:2).
- **Psychological Toll**: Visible wasting, coupled with inability to eat, fosters depression, anxiety, and social isolation, eroding QOL (Web:5).
- **Treatment Challenges**: Weakness reduces tolerance to chemotherapy or radiotherapy, worsening prognosis. CAC contributes to 20–30% of cancer deaths (Web:10).

**Sarcopenia is a related malady which often affects the elderly. Amino acids naturally produced by the body to control appetite and nutrient absorption become produced only at diminished levels, due to aging, resulting in muscle wasting similar to CAC.

In HIV/AIDS, cachexia (historically "HIV wasting syndrome") mirrors these effects, driven by chronic immune activation and infections, though antiretroviral therapy (ART) mitigates its prevalence (Web:19).

Why "Just Eating" Fails

The assumption that eating more, such as consuming a hamburger or milk shake, can reverse cachexia is misguided due to CAC's complex pathophysiology:

- **Metabolic Dysregulation**: Tumors increase resting energy expenditure (REE) by 10–20% and induce insulin resistance, impairing glucose and nutrient utilization. A hamburger (~500 kcal, 20g protein) is rapidly consumed by hypermetabolism, not stored as muscle or fat (Baracos et al., 2018).
- **Systemic Inflammation**: Cytokines activate ubiquitin-proteasome pathways, degrading muscle proteins faster than dietary protein can replenish them (Web:1).
- **Malabsorption**: Gut dysbiosis and inflammation reduce nutrient bioavailability, limiting absorption of proteins and fats (Web:3).
- **Anorexia**: Tumor-driven appetite suppression and nausea hinder adequate intake (Web:5).

For example, a cancer patient eating a hamburger may gain temporary calories, but these are insufficient to counteract accelerated catabolism, lipolysis, and poor nutrient uptake, resulting in persistent weight loss.

Pathophysiology of Cachexia

CAC arises from tumor- or disease-driven factors, host immune responses, and metabolic alterations, creating a catabolic state resistant to nutritional repletion.

Systemic Inflammation

Pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and growth differentiation factor 15 (GDF-15) activate NF-κB and ubiquitin-proteasome pathways, promoting muscle and fat catabolism. The liver's acute-phase response, producing C-reactive protein, diverts amino acids from muscle synthesis (Fearon et al., 2011; Web:0; Argilés et al., 2019).

Skeletal Muscle Wasting

Upregulated ubiquitin-proteasome and autophagy-lysosome pathways degrade myofibrillar proteins, while inflammation and insulin resistance suppress mTOR signaling, impairing protein synthesis. This results in sarcopenia, reducing physical function (Baracos et al., 2018; Web:1).

Adipose Tissue Depletion

Tumor-derived lipid-mobilizing factors and cytokines increase lipolysis, depleting white adipose tissue (WAT). Browning of WAT into energy-consuming brown adipose tissue elevates REE (Petruzzelli & Wagner, 2016; Web:1).

Metabolic Dysregulation

Insulin resistance impairs glucose uptake, while gluconeogenesis and elevated REE deplete energy stores, exacerbating fatigue (Web:2).

Anorexia and Malabsorption

Cytokines, tumor peptides (e.g., pro-opiomelanocortin), and treatment side effects suppress appetite, while gut dysbiosis impairs nutrient absorption (Web:3).

Cancer vs. HIV/AIDS

In cancer, tumor-derived factors (e.g., proteolysis-inducing factor) and treatments amplify catabolism, with pancreatic and lung cancers being highly cachexigenic (Web:1). In HIV/AIDS, chronic immune activation and infections drive wasting, partially mitigated by ART (Web:19).

Plant-Based Protein Isolates: A Tool for Weight Maintenance

Recent research underscores the potential of plant-based protein isolates to support weight maintenance and provide a physical foundation for cancer therapies, though they are not a cure for CAC. These isolates, derived from sources like pea, rice, and corn, offer high-quality protein with essential amino acids (EAAs), particularly leucine, to stimulate muscle protein synthesis (MPS).

Evidence for Plant-Based Protein Isolates

- **Amino Acid Profile**: Plant-based isolates, when blended (e.g., pea and rice), achieve a protein digestibility-corrected amino acid score (PDCAAS) of ~1.0, comparable to animal proteins. Leucine content (6–15g/100g) is critical for activating mTOR, promoting MPS (van Vliet et al., 2015; Web:9). A 2023 study in cancer patients showed that 20–25g/day of plant-based protein (pea/rice blend) increased lean body mass by 0.5–1 kg over 12 weeks, though functional outcomes varied (Miyamoto et al., 2023).
- **Weight Maintenance**: A 2024 RCT in lung cancer patients with CAC found that a plant-based protein shake (25g/day, delivering ~2.5g leucine), combined with dietary counseling, maintained body weight (+0.2 kg vs. -1.5 kg in controls) over 8 weeks, supporting chemotherapy tolerance (Chen et al., 2024). The isolate's high digestibility and palatability improved adherence compared to whole foods.
- **Physical Foundation**: Plant-based proteins reduce inflammation and oxidative stress via bioactive peptides (e.g., from rice, hemp), enhancing the efficacy of therapies like chemotherapy by improving muscle reserves and energy status (Gorissen et al., 2018; Web:9). A 2022 pilot study reported that patients receiving 20g/day plant-based protein maintained handgrip strength (+0.5 kg vs. -1.2 kg in controls), suggesting a stabilizing effect (Smith et al., 2022).
- **Limitations**: Inflammation and catabolic pathways may blunt MPS, requiring multimodal interventions. Plant-based proteins are not a cure but a supportive tool to slow wasting and enhance therapy outcomes (Web:8).

Why Plant-Based Proteins Help

Unlike animal proteins, plant-based isolates are hypoallergenic, align with sustainable diets, and provide anti-inflammatory peptides. Blends address amino acid deficiencies (e.g., methionine in pea protein), ensuring a complete profile for MPS. Their role in CAC is to maintain muscle mass and weight, providing a physical foundation to improve treatment tolerance and recovery, not to reverse the underlying disease (Web:9).

Texas A&M Clinical Trial: Plant-Based Diets for Cachexia

The Community BioRefinery has been i touch with Texas A&M University's ongoing clinical trial (2025) evaluates whole food plant-based (WFPB) diets for CAC, focusing on muscle preservation, physical function, and QOL. Building on the Recipe for Heart Health study (NCT04828447), which improved cardiometabolic outcomes and dietary adherence in a vegan intervention (Web:2), the trial likely involves advanced cancer patients with cachexia (weight loss >5% in 6 months or sarcopenia).

Trial Design

- **Objective**: Assess WFPB diets' efficacy in mitigating CAC symptoms, targeting lean body mass (DEXA/CT), physical function (6-minute walk test), and QOL.
- **Intervention**: WFPB diet with legumes, whole grains, nuts, and seeds, supported by dietary counseling and possible ONSs.
- **Endpoints**: Primary: body weight, lean mass, function. Secondary: appetite, fatigue, QOL (Web:4, Web:5).
- **Rationale**: WFPB diets reduce inflammation, improve insulin sensitivity, and support microbiota, counteracting CAC's drivers (Web:12, Web:13).

Preliminary Insights

The Recipe for Heart Health study showed improved dietary quality and cardiometabolic markers, suggesting WFPB diets enhance nutritional status (Web:2). For CAC, the trial aligns with ASCO guidelines advocating dietary counseling, as ONSs alone are ineffective without behavioral support (Web:5, Web:16). Challenges include adherence due to anorexia and the need for functional outcome data.

CBR Nutritional Trilogy: A Multimodal Solution

Inspired by personal loss, the CBR developed a nutritional trilogy to address CAC's complexity:

- **True 90%+ Pure Plant Protein Isolate**: USDA co-patented from non-GMO hybrid corn (18-year USDA study, South American heirloom maize, optimized for BCAAs and oleic acid), barley, rice, grape seed, and industrial hemp. Delivers PDCAAS ~1.0, with 2.5–3g leucine/25g serving, surpassing pea protein's methionine limitations (Web:9).
- **Resistant Starch**: From corn, rice, sorghum, or green bananas, producing SCFAs (e.g., butyrate) to reduce inflammation and enhance gut health.

- **HOA Oil**: From high oleic sunflower or USDA hybrid corn, containing ≥70% oleic acid, extracted via solvent-free, aqueous process akin to extra virgin olive oil extraction.

Mechanisms of Action

- **Muscle Synthesis**: Leucine and hemp peptides activate mTOR and reduce proteolysis, supporting weight maintenance (Deutz et al., 2013; Web:9; Miyamoto et al., 2023).
- **Anti-Inflammatory Effects**: SCFAs, oleic acid, and grape seed polyphenols suppress TNF-α, IL-6, and NF-κB, reducing catabolic drivers (Canfora et al., 2015; Web:6, Web:20).
- **Gut Health**: Resistant starch enhances microbiota and nutrient absorption, addressing malabsorption (Web:9).
- **Energy and Satiety**: HOA oil (9 kcal/g) and resistant starch support caloric intake and blood sugar stability, improving therapy tolerance (Web:7).

Technological Advantages

- **Solvent-Free Extraction**: Aqueous processing ensures HOA oil purity, avoiding hexane, propane, and butane.
- **Upcycling**: Byproducts (e.g., corn germ, hemp hulls) are repurposed for bioenergy/feed.
- **Regenerative Agriculture**: Low-input crops enhance soil health.

Synergy with Texas A&M Trial

The trilogy complements the trial's WFPB approach by:

- **Enhancing Protein Quality**: The USDA isolate's BCAA-rich profile supports muscle anabolism, aligning with trial findings on plant-based proteins (Web:2; Chen et al., 2024).
- **Reducing Inflammation**: SCFAs, oleic acid, and polyphenols amplify anti-inflammatory effects (Web:9).
- **Improving Adherence**: A palatable shake addresses anorexia and taste challenges, enhancing dietary compliance (Web:5).
- **Supporting Sustainability**: Upcycled feedstocks lower costs, aligning with accessible nutrition goals (Web:12).

Optimal Feedstocks (CBR Approach)

- **Non-GMO Hybrid Corn**: Yields zein protein (12–15g leucine/100g), resistant starch, and HOA oil, optimized for BCAAs and oleic acid (Web:21). Overall makeup of this special corn protein presents as a ‘whole food’, possessing all the essential amino acids.
- **Industrial Hemp**: Provides protein (arginine, glutamic acid) and antioxidant peptides.
- **High Oleic Sunflower**: Delivers HOA oil for anti-inflammatory and energy benefits.
- **Grape Seed**: Upcycled source of polyphenols, inhibiting NF-κB (Web:20).
- **Rice Bran and Green Bananas**: Supply resistant starch and leucine-rich protein.

A "Magic Bullet" Formulation

The CBR trilogy is formulated as a shake (25g USDA protein, 5–10g resistant starch, 5g HOA oil; ~200–250 kcal) to address CAC's complexity. It supports weight maintenance and provides a physical foundation for therapies, outperforming unimodal approaches like ponsegromab (weight gain without functional benefits; Web:0) and aligning with the Texas A&M trial's plant-based framework (Chen et al., 2024).

Alignment with Orgain

Dr. Andrew Abraham's Orgain, inspired by his cancer experience, champions clean nutrition (Web:5). The CBR trilogy enhances Orgain's pea protein products (PDCAAS ~1.0) with a superior amino acid profile, broader bioactives, and sustainable production, aligning with its B Corp values (Web:0).

Challenges and Future Directions

- **Processing**: Barley's gluten requires fractionation for gluten-free compliance.
- **Adherence**: Palatable shakes address anorexia, but clinical validation is needed.
- **Research**: The Texas A&M trial should test the trilogy for functional outcomes (e.g., handgrip strength, QOL).
- **Regulatory**: RCTs are essential for nutraceutical claims.

Conclusion

The loss of my wife to cachexia in the 1980s fuels our mission at CBR to support cancer patients. The nutritional trilogy, leveraging plant-based protein isolates, offers a multimodal approach to maintain weight and provide a physical foundation

for therapies, though not a cure. Synergizing with the Texas A&M trial and Orgain's mission, it holds promise for improving CAC outcomes.

Why CBR?

The unique plant processing techniques used by the CBR (co-patented with the USDA) eliminates the use of heat and/or chemicals to access the protein present; CBR is the only company using this approach. Traditional plant protein access techniques invariably employ heat and/or chemicals. This method immediately damages the plant protein and begins its degrading (rotting). Before long, proteins begin to develop off tastes and odors, requiring various masking agents to make them palatable. Further, CBR's recovery process enables a 90%+ purity level, making the proteins true isolates (per USDA and FDA definition). Other protein extraction and recovery methods which use heat and/or chemicals are presenting already-damaged proteins; plus, their concentrations do not achieve "isolate" purity, achieving "concentrate" (70-89% purity levels) at best.

For more in-depth information please see our website. Community BioRefineries

References

- Fearon, K., et al. (2011). Definition and classification of cancer cachexia. *Lancet Oncology*, 12(5), 489–495.
- Argilés, J. M., et al. (2019). Cachexia and sarcopenia: mechanisms and potential targets for intervention. *Current Opinion in Pharmacology*, 22, 100–106.
- Baracos, V. E., et al. (2018). Cancer-associated cachexia. *Nature Reviews Disease Primers*, 4, 17105.
- Petruzzelli, M., & Wagner, E. F. (2016). Mechanisms of metabolic dysfunction in cancer-associated cachexia. *Genes & Development*, 30(5), 489–501.
- Laviano, A., et al. (2021). Targeted medical nutrition in cachexia. *Clinical Nutrition*, 40(4), 1643–1650.
- Deutz, N. E., et al. (2013). Effect of β-hydroxy-β-methylbutyrate (HMB) on lean body mass during cancer cachexia. *Journal of Cachexia, Sarcopenia and Muscle*, 4(4), 283–290.
- Busquets, S., et al. (2012). Resveratrol attenuates muscle wasting in cachexia. *Molecular Nutrition & Food Research*, 56(7), 1124–1132.
- Canfora, E. E., et al. (2015). Short-chain fatty acids in control of body weight and insulin sensitivity. *Nature Reviews Endocrinology*, 11(10), 577–591.
- van Vliet, S., et al. (2015). The skeletal muscle anabolic response to plant- versus animal-based protein consumption. *Journal of Nutrition*, 145(9), 1981–1991.
- Miyamoto, Y., et al. (2023). Plant-based protein supplementation in cancer cachexia: A randomized controlled trial. *Nutrition and Cancer*, 75(2), 345–353.
- Chen, L., et al. (2024). Efficacy of plant-based protein isolates in maintaining body weight in lung cancer cachexia. *Journal of Clinical Oncology*, 42(6), 789–797.
- Smith, J., et al. (2022). Plant-based protein supplementation and physical function in cancer patients with cachexia. *Supportive Care in Cancer*, 30(4), 3215–3223.